These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27823792)

  • 41. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
    Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
    Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
    Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
    Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-dose apixaban in extended treatment of cancer-associated thrombosis: Less is more?
    Barca-Hernando M; Marin-Romero S; Jara-Palomares L
    J Thromb Haemost; 2022 May; 20(5):1070-1072. PubMed ID: 35445577
    [No Abstract]   [Full Text] [Related]  

  • 44. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
    King DA; Pow RE; Dickison DM; Vale PR
    Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of apixaban-associated subdural hematoma: a case report on the use of factor eight inhibitor bypassing activity.
    Rinehart DR; Lockhart NR; Hamilton LA; Langdon JR; Rowe AS
    Crit Care Med; 2015 Jun; 43(6):e203-7. PubMed ID: 25738855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An Adult Woman With Stage 4 Chronic Kidney Disease and a Diffuse Rash.
    Aalaei-Andabili SH; Umer M; Keeley EC
    JAMA Cardiol; 2019 May; 4(5):492. PubMed ID: 30942843
    [No Abstract]   [Full Text] [Related]  

  • 48. Direct oral anticoagulant drugs (DOAC).
    Blum RA; Lindfield D
    J Cataract Refract Surg; 2016 Jan; 42(1):171-2. PubMed ID: 26948793
    [No Abstract]   [Full Text] [Related]  

  • 49. Spontaneous splenic rupture associated with apixaban: a case report.
    Lowry LE; Goldner JA
    J Med Case Rep; 2016 Aug; 10(1):217. PubMed ID: 27506776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
    Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
    Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Proper use of apixaban: an outline for clinical practice].
    Albaladejo P; Deplanque D; Fossati F; Mahagne MH; Mismetti P; Nguyen P; Roy P; Touze E; Mourad JJ
    J Mal Vasc; 2014 Dec; 39(6):409-25. PubMed ID: 25451020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spontaneous spinal subdural haematoma in a patient on apixaban.
    Mchaourab A; Evans GYR; Austin R
    BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30674492
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.
    Sivolella S; De Biagi M; Brunello G; Berengo M; Pengo V
    Odontology; 2015 Sep; 103(3):258-63. PubMed ID: 25656043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New oral anticoagulants in patients with atrial fibrillation in a urban health center].
    Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F
    Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157
    [No Abstract]   [Full Text] [Related]  

  • 55. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
    van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
    Trials; 2015 Sep; 16():393. PubMed ID: 26340977
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval.
    Frost C; Nepal S; Byon W; Moore K; Reeves RA; Boyd R; LaCreta F
    J Clin Pharmacol; 2015 May; 55(5):549-55. PubMed ID: 25501868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
    Chang M; Yu Z; Shenker A; Wang J; Pursley J; Byon W; Boyd RA; LaCreta F; Frost CE
    J Clin Pharmacol; 2016 May; 56(5):637-45. PubMed ID: 26358690
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
    Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
    Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update.
    Cappellari M; Bovi P
    Thromb Haemost; 2015 Aug; 114(2):440-4. PubMed ID: 25809649
    [No Abstract]   [Full Text] [Related]  

  • 60. [Gastrointestinal bleeding during treatment with non­vitamin K antagonist oral anticoagulants (NOACs) may be caused by malignant lesions].
    Haeggström A; Risberg D; Al-Kahlili F; Gilstring Å; Tullberg U; Wallén H
    Lakartidningen; 2016 Nov; 113():. PubMed ID: 27824386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.